News

GW Pharmaceuticals Plc has raised $300 million in a secondary offering on the US Nasdaq, providing it with capital to commercialise its recently approved cannabinoid medicine Epidiolex for the treatment of seizures associated with the childhood epilepsies, Lennox-Gastaut syndrome and Dravet syndrome.

Epidiolex was approved by the US Food and Drug Administration on 25 June. The medicine is currently under review at the European Medicines Agency with a decision expected in the first quarter of 2019.

Two scientists who identified proteins which act as a break on the immune system have been awarded the 2018 Nobel Prize in Physiology or Medicine for their discovery, which is the scientific basis for the ‘immune checkpoint’ class of medicines. James P. Allison, who discovered CTLA-4, and Tasuku Honjo, who discovered PD-1, were cited by the Nobel Assembly at Karolinska Institutet for their landmark work in the global fight against cancer. Both proteins can prevent the immune system from recognising cancer cells.

Forbion Capital Partners of the Netherlands has closed its previously-announced Forbion IV biopharma fund at €360 million, significantly above the original target of €250 million. Forbion IV, like its predecessor fund Forbion III, will primarily invest in life science opportunities in the EU, including the UK, with the remainder targeting North America.

Scientists from University College London have identified a second source of endothelial cells that line the interior of blood vessels, potentially opening up a path for exploring the use of stem cells to grow new blood vessels and repair damaged ones.

An enzyme therapy developed by Hansa Medical AB has successfully inactivated donor-specific antibodies in patients with kidney disease enabling them to receive kidney transplants. The result comes from follow-up data from two Phase 2 trials of highly sensitised patients who otherwise would not have been eligible for transplantation.

Novartis has announced plans to reduce its workforce in Switzerland and the UK by a net 2,100 over four years as it shifts away from the production of high volume pharmaceutical products to personalised medicines such as gene therapies. The shift represents a focus on higher-value specialised products.

Among the activities that will be curtailed is the production of active pharmaceutical ingredients at a plant in the UK. Novartis plans to divest or close the manufacturing site in Grimsby which currently employs just under 400 people.

The checkpoint protein on immune cells may have another role to play in treating disease besides fighting cancer. This is the proposition being put forward by Altheia Science Srl, a new Italian biotech which is building a pipeline of agents to modulate programmed cell death-1 (PD-1) and its ligand (PD-L1) for the treatment of Type 1 diabetes and multiple sclerosis.

Nightstar Therapeutics Plc has reported positive Phase 1/2 data from a trial of its gene therapy for X-linked retinitis pigmentosa, a rare inherited retinal disorder primarily affecting males. The 18-patient study showed preliminary evidence of improved visual function.

A study published in the journal Science on 7 September 2018 gives new insights into how exercise can improve memory and possibly help prevent or treat Alzheimer’s disease. The corollary is that pharmaceutical treatments might be designed to mimic this effect.

The European Medicines Agency has delivered a positive opinion recommending use of a new gene therapy, Luxturna (voretigene neparvovec), to treat adults and children suffering from an inherited retinal dystrophy caused by mutations in the RPE65 gene.

The disease causes vision loss that usually leads to blindness. There is currently no treatment for the disorder. Support to patients is limited to measures allowing disease management such as wearing a medical identification bracelet.